{
    "clinical_study": {
        "@rank": "131352", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in  neonates\n      with symptomatic congenital cytomegalovirus infection with central nervous system disease."
        }, 
        "brief_title": "Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection", 
        "condition": "Cytomegalovirus Infections", 
        "condition_browse": {
            "mesh_term": "Cytomegalovirus Infections"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized study.  Patients are stratified by participating\n      institution.\n\n      Patients are randomly assigned to no antiviral therapy or intravenous ganciclovir every 12\n      hours for 6 weeks.\n\n      Patients are followed at weeks 1-4 and 12, months 6, 12, 24, 36, 48, and 60, and yearly\n      thereafter until puberty (when possible)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Symptomatic cytomegalovirus (CMV) infection: Central nervous system disease, with or\n             without other organ system involvement, e.g.: Microcephaly, i.e., less than 5% for\n             age Radiologic changes indicating brain disease Cerebrospinal fluid exam abnormal for\n             age Chorioretinitis Hearing defects\n\n          -  CMV confirmed by urine, throat, buffy coat, and/or conjunctiva culture\n\n          -  No hydroencephalopathy or other devastating brain involvement\n\n        --Prior/Concurrent Therapy--\n\n          -  No concurrent antiviral agent No concurrent immune globulin\n\n        --Patient Characteristics--\n\n          -  Age: Under 1 month (preferably under 2 weeks)\n\n          -  Life expectancy: No imminent demise\n\n          -  Renal: Creatinine no greater than 1.5 mg/dL\n\n          -  Other: Birth weight at least 1200 g Gestational age at least 32 weeks No HIV\n             infection No concurrent bacterial infection Eligible if resolved following 2-week\n             treatment and CMV symptoms persist"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "1 Month", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "130", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004278", 
            "org_study_id": "199/11689", 
            "secondary_id": "NIAID-558607"
        }, 
        "intervention": {
            "intervention_name": "ganciclovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ganciclovir"
        }, 
        "keyword": [
            "congenital cytomegalovirus infection", 
            "cytomegalovirus infection", 
            "herpesvirus infection", 
            "immunologic disorders and infectious disorders", 
            "neonatal disorders", 
            "rare disease", 
            "viral infection"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "last_name": "Richard J. Whitley", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004278"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1991", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2000"
    }, 
    "geocoordinates": {}
}